Inversago Pharma picks up $35m in Forbion-led Series B
Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.
Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination